Saeedi R, Mojebi-Mogharar A, Sandhu SK, Dubland JA, Ford Jo-Ann, Yousefi M, Pudek M, Holmes DT, Erb SR, Peter KWC, Kendler DlL, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 19
Paginas: 207-214
Archivo PDF: 152.23 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gua R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol 2011; 91: 8017.

2. Köklü S, Tuna Y, Gülsen MT, Demir M, Köksal AS, Koçkar MC, Aygün C, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis b virus-related cirrhosis. Clin Gastroenterol Hepatol 2013; 11: 88-94.

3. Wong V, Chan H. Chronic hepatitis B: A treatment update. Semin Liver Dis 2013; 33: 122-9.

4. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open label follow-up study. Lancet 2013; 381: 468-75.

5. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49:S185-S195.

6. Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, Kallis YN, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis 2015; 211: 374-82.

7. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-80.

8. Saeedi R, Jiang SY, Holmes DT, Kendler DL. Fibroblast Growth Factor 23 is Elevated in Tenofovir-Related Hypophosphatemia. Calcified Tissue International 2014; 94: 665- 8.

9. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 1317-25.

10. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus the tenofoviremtricitabine in HIV-infected adults: 48 week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-72.

11. Wanner DP, Tyndall A, Walker UA. Tenofovir-induced osteomalacia. Clin Exp Rheumatol 2009; 27: 1001-3.

12. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Carlson AE, Mansky KC. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun 2010; 394: 48-53.

13. Ramon I, Kleynen P, Body JJ, Karmali R. Fibroblast growth factor 23 and its role in phosphate homeostasis. Eur J Endocrinol 2010; 162: 1-10.

14. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphonate homeostasis. J Bone Miner Res 2004; 19: 429-35.

15. Tourret J, Deray G, Isnard-Bagnis C. Assessment of the feasibility of using sunlight exposure to obtain the recommended level of vitamin D in Canada. CMAJ Open 2015; 3: E258-E63.

16. Shimizu Y, Hiraoka A, Yamago H, Shiraishi A, Imai Y, Tatsukawa H, Tanihira T, et al. Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy. Hepatol Res 2014; 44: 1081-7.

17. Girgis CM, Wong T, Ngu MC, Emmett L, Archer KA, Chen RC, Seibel MJ. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol 2011; 45: 468-73.

18. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag 2010; 2(6): 41-7.

19. Lane NE, Parimi N, Corr M, Yao W, Cauley JA, Nielson CM, Ix JH, et al. Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 2013; 28: 2325-32.